Open AccessDevelopment of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report
Author(s) -
Na Zhang,
Ting-De Jiang,
Shuhua Yi
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i14.4698
Subject(s) - multiple myeloma , dyscrasia , monoclonal gammopathy of undetermined significance , medicine , plasma cell , myeloid leukemia , dasatinib , tyrosine kinase inhibitor , plasma cell leukemia , cancer research , plasma cell dyscrasia , bone marrow , leukemia , haematopoiesis , stem cell , monoclonal , plasma cell myeloma , hematopathology , immunology , imatinib , immunoglobulin light chain , monoclonal antibody , biology , cancer , antibody , cytogenetics , genetics , biochemistry , chromosome , gene
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell dyscrasias in the same patient is an extremely rare incident and has been reported in several cases in the literature.